Scancell Holdings Plc
31 July 2026
31 July 2026
Scancell Holdings plc
("Scancell" or the "Company")
Extension of exercise period for CSO share options
Scancell (AIM: SCLP), the developer of active immunotherapies to treat cancer, announces that the exercise period for 3.85 million share options awarded to Lindy Durrant, Chief Scientific Officer of the Company, on 30 July 2020 has been extended from 30 July 2026 to 31 January 2027.
These options have an exercise price of 4.5 pence each. All other conditions of the award remain the same.
The extension of the expiry date for the share options amounts to a related party transaction within the meaning of the AIM Rules for Companies. The Directors who are independent of the related party transaction (being all the Directors of the Company other than Lindy Durrant) having consulted with Panmure Liberum, the Company's nominated adviser, consider this proposed extension of the expiry date to be fair and reasonable insofar as the shareholders of the Company are concerned.
For the purposes of UK MAR, the person responsible for arranging for the release of this announcement on behalf of the Company is Phil L'Huillier, CEO.
For further information, please contact
|
Scancell Holdings plc Phil L'Huillier, CEO Jean-Michel Cossery, Chairman David Schilansky, CFO |
+44 (0) 20 3709 5700 |
|
Panmure Liberum (Sole Placement Agent, Nominated Adviser and Joint Broker] Emma Earl, Will Goode, Mark Rogers (Corporate Finance) Rupert Dearden (Corporate Broking) |
+44 (0) 20 7886 2500 |
|
WG Partners LLP (Joint Broker) Claes Spang |
+44 (0) 20 3705 9330 |
|
Investor and media relations Mandeep Sehmi |
+44 (0) 1865 582 066 mandeepsehmi@Scancell.co.uk |
About Scancell
Scancell (LSE:SCLP; www.scancell.co.uk) is a clinical stage biotechnology company developing targeted off-the-shelf novel immunotherapies, to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, the lead product from their DNA ImmunoBody® platform has demonstrated safe, durable and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in a Phase 2 trial in melanoma. Modi-1, the lead peptide immunotherapy from their Moditope® platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, Scancell's wholly owned subsidiary, GlyMab Therapeutics Ltd., has been established with the intention to hold and develop an exciting early-stage pipeline of high affinity GlyMab® antibodies targeting tumour specific glycans, two of which already have been licensed and are being developed by Genmab A/S, an international biotechnology company and global leader in the antibody therapeutics space.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.